Lebrikizumab Provides Rapid Response in EASI Components and Itch in Moderate-to-Severe Atopic Dermatitis

Eric  Simpson; Gil  Yosipovitch; Kilian  Eyerich; Delphine  Staumont-Sallé; Mona  Shahriari; Gaia  Gallo; Eric  Wolf; Evangeline  Pierce; Chunyuan  Liu; Jinglin  Zhong; Helena  Agell; Marjolein  de Bruin-Weller

doi:10.25251/skin.7.supp.279

Eric Simpson

Oregon Health & Science University, Portland, USA

Gil Yosipovitch

University of Miami Miller School of Medicine, Miami, USA

Kilian Eyerich

University of Freiburg, Germany

Delphine Staumont-Sallé

University of Lille, Lille, France

Mona Shahriari

Yale University School of Medicine, New Haven, USA

Gaia Gallo

Eli Lilly and Company, Indianapolis, USA

Eric Wolf

Eli Lilly and Company, Indianapolis, USA

Evangeline Pierce

Eli Lilly and Company, Indianapolis, USA

Chunyuan Liu

TigerMed Inc, Somerset, USA

Jinglin Zhong

IQVIA, Durham, USA

Helena Agell

Almirall, S.A., Barcelona, Spain

Marjolein de Bruin-Weller

University Medical Center Utrecht, The Netherlands

Keywords

Lebrikizumab, EASI, itch, atopic dermatitis, rapid response

References

1. Okragly AJ, et al. DermatolTher (Heidelb). 2023;13:1535-1547.

2. Ratnarajah K, et al. J Cutan Med Surg. 2021;25:315-328.

3. Silverberg JI, et al. N Engl J Med. 2023;388:1080-1091.

4. Blauvelt A, et al. Br J Dermatol. 2023;188:740-748.

5. Simpson EL, et al. JAMA Dermatol. 2023;159:182-191

6. Yosipovitch G, et al. Br J Dermatol. 2019;181:761-769.

PDF

Published

Nov 13, 2023

DOI https://doi.org/10.25251/skin.7.supp.279

How to Cite

Simpson, E. ., Yosipovitch, G. ., Eyerich, K. ., Staumont-Sallé, D. ., Shahriari, M. ., Gallo, G. ., Wolf, E. ., Pierce, E. ., Liu, C. ., Zhong, J. ., Agell, H. ., & de Bruin-Weller, M. . (2023). Lebrikizumab Provides Rapid Response in EASI Components and Itch in Moderate-to-Severe Atopic Dermatitis. SKIN The Journal of Cutaneous Medicine, 7(6), s279. https://doi.org/10.25251/skin.7.supp.279

Issue

Vol. 7 No. 6 (2023): November 2023 Issue

Section

Atopic Dermatitis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Amy Paller, Andrew Blauvelt, Weily Soong, Shinichi Imafuku, Chih-ho Hong, Marie Schuttelaar, Petra Amoudruz, Azra Kurbasic, Lise Soldbro, Katja Lophaven, Michael Cork, Anthony Bewley, Eric Simpson, Efficacy and safety of tralokinumab in adolescents with moderate-to- severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Eric Simpson, Andrew Blauvelt, Emma Guttman-Yassky, Margitta Worm, Charles Lynde, Hidehisa Saeki, Yves Poulin, Andreas Wollenberg, Efficacy and Safety of Tralokinumab Monotherapy in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from Two 52-Week, Phase 3 Trials (ECZTRA 1 and ECZTRA 2) , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Kim Papp, Jacek Szepietowski, Leon Kircik, Darryl Toth, Michael Kuligowski, May Venturanza, Kang Sun, Eric Simpson, Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Pooled Analysis of Two Phase 3, Randomized, Double-Blind Studies , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
Eric Simpson, Joseph Merola, Jonathan Silverberg, Rebecca Zachariae, Rebecca Olsen, Andreas Wollenberg, Safety of Specifically Targeting Interleukin 13 with Tralokinumab in Adult Patients with Moderate-To-Severe Atopic Dermatitis: Pooled Analysis of Five Randomized, Double-Blind, Placebo-Controlled Phase 3 and Phase 2 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
Kim Papp, Jacek Szepietowski, Leon Kircik, Darryl Toth, Lawrence Eichenfeld, Seth Forman, Michael Kuligowski, May Venturanza, Kang Sun, Eric Simpson, Long-Term Safety and Disease Control With Ruxolitinib Cream in Atopic Dermatitis: Results From Two Phase 3 Studies , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Lawrence Eichenfeld, Eric Simpson, Kim Papp, Jacek Szepietowski, Leon Kircik, Darryl Toth, Seth Forman, Michael Kuligowski, May Venturanza, Haobo Ren, Amy Paller, Long-Term Safety and Disease Control of Ruxolitinib Cream Among Adolescents With Atopic Dermatitis: Results From Two Phase 3 Studies , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Andrew Blauvelt, Anderas Wollenberg, Andrew Pink, Ketty Peris, April Armstrong , Lynda Spelman, Hidehisa Saeki, Charles Lynde, Pedro Herranz, Sebastien Barbarot, Eric Simpson, Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: combined results from two phase 3, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2) , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Andrew Blauvelt, Jacek Szepietowski, Kim Papp, Eric Simpson, Jonathan Silverberg, Brian Kim, Shawn Kwatra, Michael Kuligowski, May Venturanza, Kang Sun, Leon Kircik, Itch-Free State in Patients With Atopic Dermatitis Treated With Ruxolitinib Cream , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Jonathan Silverberg, Sebastien Barbarot, Melinda Gooderham, Jan Simon, Eric Simpson, Azra Kurbasic, Christina Olsen, Michael Cork, Specifically Targeting Interleukin-13 with Tralokinumab Improved Sleep in Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials in Patients with Atopic Dermatitis , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
Eric Simpson, Leon Kircik, Andrew Blauvelt, Michael Kuligowski, May Venturanza, Kang Sun, Lawrence Eichenfeld, Long-Term Safety and Disease Control With Ruxolitinib Cream in Patients With More Severe Atopic Dermatitis: Pooled Results From Two Phase 3 Studies , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)

1 2 3 4 5 > >>

Main Article Content

Keywords

References

Article Sidebar

Article Details

Most read articles by the same author(s)